Nuwellis (NUWE) Stock Analysis & Winston Score

Nuwellis, Inc. is a small medical device company focused on a treatment called aquapheresis, which removes excess fluid from patients with conditions like heart failure and kidney disease. Its main product is the Aquadex FlexFlow system — a machine used in hospitals and clinics to filter fluid directly from a patient's blood. The company sells primarily to hospitals in the United States. Nuwellis makes money by selling the Aquadex machines to hospitals and then generating recurring revenue from the single-use disposable sets required for each treatment. It operates almost entirely in the U.S. and is a very small company, with a market cap near zero and deeply negative operating margins, meaning it spends far more than it earns. The key challenge is convincing more hospitals to adopt aquapheresis over standard drug-based fluid removal, and the company faces serious financial pressure to grow revenue fast enough to survive as a going concern.